The type I CRISPR protein Cas3 works like Pac-Man, chomping away at a continuous stream of nucleotides with intrinsic activity for introducing targeted large deletions from a few hundred base pairs to ...

A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...

New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...

Researchers at Gladstone Institutes (CA, USA) have mapped the human immune response using next-generation CRISPR technology known as base editing. Using this tool, the team was able to identify ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

BUFFALO, NY- November 28, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on November 27, 2023, entitled, “The double-edge sword of CRISPR application for in vivo studies.” In ...

CRISPR is a revolutionary tool that allows scientists to precisely modify the genome and gene expression of cells in any organism. It's a reagent - a substance that facilitates a reaction - that ...

The "Plant Breeding and CRISPR Plants - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Plant Breeding and CRISPR Plants was valued at ...